drugset / Trial / NCT05296512
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research study is being done to test the efficacy and safety of combining the study drugs pembrolizumab and lenvatinib in patients with clear cell ovarian cancer. The names of the study drugs involved in this study are: * Lenvatinib * Pembrolizumab
Timeline
- Start
- 2022-09-23
- Primary completion
- 2026-09-23
- Completion
- 2028-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |